Treatment

In order for positive treatment outcomes to be sustained, HCV treatment programs must address the barriers patients face at multiple levels and implement system-level changes. More

People living with or at risk of hepatitis C virus, health care providers, and policymakers in low- and middle-income countries showed significant interest in a potential long-acting HCV cure, recent surveys have found. More

DAAs achieve a 95% success rate in treating HCV among HIV patients, but 5% experience unsuccessful treatment; Lower CD4 cell counts, HCV genotype 4, and recent injection drug use are linked to higher odds of unsuccessful treatment. More

A study explores the challenges and opportunities in long-acting HCV treatment across three LMICs: Egypt, Ethiopia and India. More

A study explores the acceptability and feasibility of long-acting HCV treatment in LMICs by surveying HCV treatment prescribers and policymakers. More

Results suggest a shorter treatment duration could reduce costs and improve access in low- and middle-income countries. More

A study identified and relinked to care HCV patients previously lost to medical follow-up in Spain using an artificial intelligence-assisted system. More

A study measures the acceptability, feasibility, and safety of an urban point-of-diagnosis HCV treatment initiation approach delivered in a non-clinical community setting, through a novel staff-facilitated telemedicine model. More

If at least 7.5% of people who inject drugs in the Chicago area use direct-acting antivirals, HCV would be eliminated from that population in 10 years. More

Findings from the TAC ANRS 12311 trial revealed the success of tailored treatment combinations to the specific genotype of HCV to optimize efficacy and minimize adverse effects. More